Literature DB >> 19394158

Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Jeff M Michalski1, Colleen Lawton, Issam El Naqa, Mark Ritter, Elizabeth O'Meara, Michael J Seider, W Robert Lee, Seth A Rosenthal, Thomas Pisansky, Charles Catton, Richard K Valicenti, Anthony L Zietman, Walter R Bosch, Howard Sandler, Mark K Buyyounouski, Cynthia Ménard.   

Abstract

PURPOSE: To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer. METHODS AND MATERIALS: An RTOG-sponsored meeting was held to define an appropriate PF-CTV after radical prostatectomy. Data were presented describing radiographic failure patterns after surgery. Target volumes used in previous trials were reviewed. Using contours independently submitted by 13 radiation oncologists, a statistical imputation method derived a preliminary "consensus" PF-CTV.
RESULTS: Starting from the model-derived CTV, consensus was reached for a CT image-based PF-CTV. The PF-CTV should extend superiorly from the level of the caudal vas deferens remnant to >8-12 mm inferior to vesicourethral anastomosis (VUA). Below the superior border of the pubic symphysis, the anterior border extends to the posterior aspect of the pubis and posteriorly to the rectum, where it may be concave at the level of the VUA. At this level, the lateral border extends to the levator ani. Above the pubic symphysis, the anterior border should encompass the posterior 1-2 cm of the bladder wall; posteriorly, it is bounded by the mesorectal fascia. At this level, the lateral border is the sacrorectogenitopubic fascia. Seminal vesicle remnants, if present, should be included in the CTV if there is pathologic evidence of their involvement.
CONCLUSIONS: Consensus on postoperative PF-CTV for RT after prostatectomy was reached and is available as a CT image atlas on the RTOG website. This will allow uniformity in defining PF-CTV for clinical trials that include postprostatectomy RT. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19394158      PMCID: PMC2847420          DOI: 10.1016/j.ijrobp.2009.02.006

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure.

Authors:  Raymond Miralbell; Hansjörg Vees; Joan Lozano; Haleem Khan; Meritxell Mollà; Alberto Hidalgo; Dolors Linero; Michel Rouzaud
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

2.  Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.

Authors:  Kirsty L Wiltshire; Kristy K Brock; Masoom A Haider; Daniel Zwahlen; Vickie Kong; Elisa Chan; Joanne Moseley; Andrew Bayley; Charles Catton; Peter W M Chung; Mary Gospodarowicz; Michael Milosevic; Andrew Kneebone; Padraig Warde; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

3.  Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.

Authors:  Philip Poortmans; Alberto Bossi; Katia Vandeputte; Mathieu Bosset; Raymond Miralbell; Philippe Maingon; Dirk Boehmer; Tom Budiharto; Zvi Symon; Alfons C M van den Bergh; Christopher Scrase; Hendrik Van Poppel; Michel Bolla
Journal:  Radiother Oncol       Date:  2007-08-13       Impact factor: 6.280

4.  MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.

Authors:  J M Silverman; T L Krebs
Journal:  AJR Am J Roentgenol       Date:  1997-02       Impact factor: 3.959

5.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

6.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

7.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

Review 8.  Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.

Authors:  R K Valicenti; L G Gomella; M Ismail; S G Mulholland; R O Petersen; B W Corn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-10-01       Impact factor: 7.038

9.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

10.  Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.

Authors:  J A Connolly; K Shinohara; J C Presti; P R Carroll
Journal:  Urology       Date:  1996-02       Impact factor: 2.649

View more
  109 in total

1.  Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer.

Authors:  Marlies Pasler; Dietmar Georg; Holger Wirtz; Johannes Lutterbach
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

2.  Shared responsibility for treatment-related morbidity for prostate cancer.

Authors:  Joseph L Chin; Glenn Bauman
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  Evaluation and optimization of the parameters used in multiple-atlas-based segmentation of prostate cancers in radiation therapy.

Authors:  Wicger K H Wong; Lucullus H T Leung; Dora L W Kwong
Journal:  Br J Radiol       Date:  2015-11-05       Impact factor: 3.039

Review 4.  Effects of radiation therapy on the structure and function of the pelvic floor muscles of patients with cancer in the pelvic area: a systematic review.

Authors:  Stéphanie Bernard; Marie-Pier Ouellet; Hélène Moffet; Jean-Sébastien Roy; Chantale Dumoulin
Journal:  J Cancer Surviv       Date:  2015-08-28       Impact factor: 4.442

5.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

6.  Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice.

Authors:  Alan Dal Pra; Cedric Panje; Thomas Zilli; Winfried Arnold; Kathrin Brouwer; Helena Garcia; Markus Glatzer; Silvia Gomez; Fernanda Herrera; Khanfir Kaouthar; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Rudolf Zwahlen; Daniel Engeler; Paul Martin Putora
Journal:  Strahlenther Onkol       Date:  2017-06-27       Impact factor: 3.621

Review 7.  Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.

Authors:  S Gwynne; E Spezi; D Sebag-Montefiore; S Mukherjee; E Miles; J Conibear; J Staffurth
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

8.  Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge.

Authors:  Emma Holliday; Clifton D Fuller; Jayashree Kalpathy-Cramer; Daniel Gomez; Andreas Rimner; Ying Li; Suresh Senan; Lynn D Wilson; Jehee Choi; Ritsuko Komaki; Charles R Thomas
Journal:  J Radiat Oncol       Date:  2015-11-03

9.  Asymmetrical Multi-task Attention U-Net for the Segmentation of Prostate Bed in CT Image.

Authors:  Xuanang Xu; Chunfeng Lian; Shuai Wang; Andrew Wang; Trevor Royce; Ronald Chen; Jun Lian; Dinggang Shen
Journal:  Med Image Comput Comput Assist Interv       Date:  2020-09-29

10.  Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips.

Authors:  I Fortin; J-F Carrier; M-C Beauchemin; D Béliveau-Nadeau; G Delouya; D Taussky
Journal:  Strahlenther Onkol       Date:  2014-02-21       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.